We raised specific antibodies in rabbits against pure aa-or yy-isoenzymes of enolase (EC 4.2.1.11) purified from human brain. After being specifically immunoabsorbed by the respective Sepharose-coupled enolase isoenzymes, the purified antibodies are desorbed by acidification and coated onto polystyrene tubes. Each sample containing the isoenzyme activity to be determined is incubated in the respective coated tube. The coating is then washed, and the reaction of the antibody-bound enzyme is initiated by adding 2-phosphoglycerate, ADP, and pyruvate kinase. The accumulation of ATP is measured by following the increase in light emission in the firefly luciferase bioluminescence system. The assay is as specific as the antibody used for coating. Its detection limit is about 5 x io U, corresponding to about 0.1 pg or 10_la mol of enzyme protein per assay. Activities of enolase isoenzymes in human plasma can be evaluated separately, rapidly, and precisely. We used the assay to measure enolase isoenzyme activities in plasma of patients suffering from different types of malignant tumors. The yy-isoenzyme of enolase (2-phospho-n-glycerate hydrolyase; EC 4.2.1.11), the so-called neuron-specific enolase, is reportedly a key enzyme in the amine precursor uptake and decarboxylation cell system (1). Recently the enzyme was detected in some endocrine tumors (2) and in serum of patients suffering from small-cell cancer of the lung (3, 4), and was used to assess the extent of disease and the response to therapy. Its activity in serum is too low for the usual photometric tests to detect the enzyme. Furthermore, serum not only contains the yy-isoenzyme, but also other enolase isoenzymes such as aa, ay, and the isoenzyme /3f3of muscle origin.' Therefore, measurements of yy.enolase in serum must be both highly specific and sensitive. Enzyme immunoassay and RIA methods have been devised (4-8), but are rather cumbersome for routine use. Here we report a new type of assay, in which the specificity of purified antibodies coupled to a solid phase is combined with the sensitivity of the firefly bioluminescence system. 
NUrtingen, F.R.G. The ATP-monitoring reagent (LKB-Wallac, Turku, Finland) was used according to the supplier's instructions.
2-Phosphoglycerate, pyruvate
kinase (EC 2.7.1.40; 200 kU/g of protein), and ATP were products of Boehringer GmbH, Mannheim, F.R.G. All other chemicals were from Merck, Darmstadt, F.R.G., and were of analytical grade.
Procedures

Photometry of enolase was done according to Bergmeyer et al. (9). Creatine kinase (EC 2.7.3.2) isoenzyme BB was assayed according
to the recommendations of the German Society for Clinical Chemistry (10). The ADP was contaminated with ATP, so we chromatographed it on Dowex 1-x8 as described by Lundin (11) . Protein was determined either by measuring the absorbance at 280 nm or by the method of Lowry et al. (12) . Bioluminescence was measured at 25 #{176}C with a luminometer (Bioluminomat LB 9500 T; Berthold, 7547 Wildbad, F.R.G.) coupled to a Servogor recorder RE 511.
General
Isoenzyme preparation.
We prepared aa-and y7-enolase isoenzymes from human brain by conventional methods ( 
13-15).
Physicochemical characterization
showed the products to be pure and homogeneous, with very similar relative molecular masses, 87 000 for aa-enolase and 86 000 for yy- BB co-chromatographs with yy-enolase in the preparation procedure, and special care must be taken to separate these two enzymes.
The co-purification of the enolase isoen.zymes from creatine kinase BB is detailed elsewhere (15). Preparation of antisera. Antibodies were raised in Chinchilla Bastard rabbits (IvACHB) by injecting 0.75 mg of the pure isoenzyme protein intradermally at several sites on the back. For the first injection we included 0.5 mL of complete Freud's adjuvant. The subsequent injections, at three-week intervals, included incomplete Freud's adjuvant. Seven days after the last injection, we collected serum from the animals. Most of them had developed antibodies after the second injection, as demonstrated by the double-diffusion test as well as by the inhibition of enolase activity in the photometric assay system (9). Figure 1 shows the lack of cross reactivity between antiaa-serum and yy.enolase or between anti-yy-serum and aaenolase, although both antisera cross reacted with the hybrid form, ay-enolase. There was also no cross reaction with purified creatine kinase BB, showing that it was not present as a contaminant.
Coupling
of pure enolase isoenzyrnes to CNBr-actwated Sepharose.
We coupled 20 mg of pure yy-enolase to CNBractivated Sepharose as follows. Thoroughly of sodium phosphate buffer (0.2 molIL, pH 7.0) and test for their activity to inhibit pure yy-enolase in the photometric assay. Pool the fractions having the highest activity, dialyze the pool against a 100-fold volume of a mixture containing, per liter, 10 mmol of sodium phosphate (pH 8.3), 10 mmol of NaHCO3, and 10 mmol of NaC1, and store the dialyzed solution at -22 #{176}C.
Use the same procedure to purify the anti-aa-antibodies.
The antibodies
purified from 100 niL of antiserum corresponded to about 8 mg of protein. Double-diffusion experiments as well as measurements of the activity-inhibiting capacity of the purified antibodies revealed the same results (not shown) as obtained with the unpurified antisera (Figure 1) . Furthermore, in double-immunodiffusion the purified anti-aa-antibodies gave a precipitation line with a crude extract of muscle.
Coating polystyrene tubes with purified antibodies. Coat 0.8 x 4 cm polystyrene tubes with purified antibodies, 16 .ig/0.3 mL, by rotating the tubes overnight at room temperature. (Measurements of protein and of the inhibiting activity of the antibody solution before and after coating indicated that about 2 g of antibody protein is adsorbed to the plastic wall of each tube.) Wash the coated tubes with several 2-mL portions of 10 g/L bovine serum albumin solution to saturate unspecific binding sites, and store at 4 #{176}C. The same coating procedure can be used with polystyrene plastic beads, 0.4 mm diameter, instead of tubes.
Solid-phase
immunobioluminescence assay for yy-enolase.
The assay for yy-enolase activity can be performed kinetically or as a fixed time assay. Table 1 summarizes the conditions of the reaction and the pipetting procedure.
For the kinetic assay, pre-incubate the sample and wash the tubes as detailed in Table 1 . Then add 480 L of the bioluminescence mixture (solutions 1-4 of step III), mix thoroughly, and initiate the reaction by adding 10 pL of the 2-phosphoglycerate solution. Measure the rate of increase in light emission. Add 10 tL of the ATP-standard solution to the sample to calibrate the assay system. An example of this type of assay is given in Figure 2 .
For the fixed-time assay pre-incubate and wash, as above, then initiate the enolase-pyruvate kinase reaction by adding 450 p.L of a mixture of 2-phosphoglycerate, pyruvate kinase, and ADP (solutions 2, 3, and 5 in Table 1 
Results and Discussion
Optimization of the Assay Conditions (Figure 4) . Independent of the concentration of the enzyme, a constant proportion, about 25%, of the enzymatic activity was inhibited by binding to the antibody, while 75% of the yy-enolase remained active in its antibody-bound forms (Figures 3 and 4) .
This indicated
that not all of the antibodies were directed against the epitope of the active center of the yy-enolase molecule. No binding of aa-enolase to tubes coated with anti-yy-antibodies could be demonstrated. The same was true for enolase activity from a crude muscle extract, but the ay-enolase hybrid reacted with the anti-yy-antibody coated on the tubes.
Of the buffer systems we tested, Tris acetate (0.1 molJl, pH 7.75) containing 2 mmol of EDTA and 10 mmol of Mg acetate per liter gave the highest yy-enolase activities with the kinetic assay system. The concentration of 2-phosphoglycerate in this assay is the same as recommended for the photometric assay (9). By using the chromatographically purified ADP (11) we could decrease the blank reaction to nearly zero in the kinetic assay. The optimal concentration of ADP was 0.5 mmol/L. Because pyruvate kinase was highly diluted in the assay system, it was not necessary to dialyze the ammonium sulfate-saturated enzyme suspension before using it in the assay. We used the ATP monitoring reagent according to the manufacturer's instructions. The optimal assay temperature was 25#{176}C. Calibration curves with pure yy-enolase in coated tubes showed that the reaction response was linearly related to enzyme content l000ng 0 Fig. 4. Lightemission as a functionof the amount of yy- (Figures 2 and 3) . By using the fixed-time assay instead of continuously monitoring the light emission, we could further lower the detection limit by 200-fold, if the proincubation interval was prolonged accordingly.
The detection range of the assay is limited mainly by two factors: the upper detection limit is fixed by the amount of antibodies coating the tubes; the lower detection limit is 
Measurement of Enolase Activities
To calculate the enzymatic activity bound to the specific antibody, one can either use a calibration curve with pure yy-enolase as a standard, or add a known amount of ATP to the assay system, using the following formula:
where ATPS is the concentration of ATP standard (in ninoll L), Se is the rate of light emission per minute (from ATP formation via the enolase-pyruvate kinase reaction), J is the immediate increase in light emission after addition of ATP standard, DF is the dilution factor, needed to express the activity as mU/L, and F is the factor to correct for enolase activity inhibited by binding to the antibody. Incubation of serum in tubes coated with anti-yy-enolase binds yy-and ay-enolase isoenzymes to the tube wall; incubation in tubes coated with anti-ay-enolase extracts the aa-and ay-dimer.
For specific detection of only one isoenzyme-for example, the yy-isoenzyme-we pre-incubate the sample first in anti-aa-coated tubes to remove a-isoenzymes activities, then we incubate the supernate in anti-yy-coated tubes. Analytical recovery experiments with pure aa-or y--enolase, respectively, show that the remaining activity is due to yy-enolase. By reversing the order of incubation, we can detect specifically the aa-isoenzymes. Table 2 gives values obtained by use of this procedure. The within-run coefficients of variation (n = 20 determinations) were 6% and 8% for the fixed-time and the kinetic assay of yy-enolase (activity: 100 mULL), respectively.
This assay measures enzyme activities. To compare our results with data obtained with methods that measure enzyme protein (3, 4, 18) , we first had to transform the activity values into enzyme concentrations.
Because we do not know the specific activities of native enolase isoenzymes.-i.e., in plasma-we used the specific activities of our purified enzymes (aa-enolase:
90 kU/g of protein; yy-enolase: 50 kU/g of protein). In general, the values for serum were greater than those for plasma, consistent with data in the literature (4) and suggesting that some of the serum enolases may be released from blood cells during clotting. Because thrombocytes, erythrocytes, and lymphocytes contain considerable amounts of the three enolase isoenzymes (4, 6), blood-cell lysis must be avoided during sampling. We therefore prefer to use plasma instead of serum.
Our calculated values (mean ± SD) for the concentrations of the three enolase isoenzymes in plasma of 40 ostensibly healthy subjects were 24 ± 10, 6.0 ± 3.2, and 3.3 ± 1.5 j.tg/L for aa-, ay-, and yy-enolase, respectively.
Kate et al. (4)
reported 20 ± 6, 4.1 ± 1.4, and 1.
In pilot studies with the solid-phase immunobioluminescence assay we measured enolase isoenzymes in plasma of some patients with various malignant diseases. In all seven patients with small-cell lung cancer we found increased yyenolase activities, two-to 20-fold the upper limit of normal. Some of these cases also had increased aa-isoenzyme activities in plasma. Again, the results are consistent with reported data (4). A patient with acute myeloid leukemia showed slightly increased yy-activities, but drastically increased aa-activities.
Patients with solid tumors generally had normal yy-activities, but some had increased aa-activities. Further detailed studies are needed to elucidate the specificity of enolase isoenzymes for detection of malignant tumors.
The analytical advantages of this solid-phase immunobioluminescence assay for enolase isoenzymes can be suimnari.zed as follows: #{149} It is highly sensitive, allowing separate determination of enolase isoenzymes in body fluids, even from healthy subjects. Measurements in cerebrospinal fluid as well as in tissue homogenates are possible. #{149} It is more specific than methods involving only specific antibodies for detection of the enzyme proteins, because measurement of enzymatic activity clearly increases the specificity of the assay. #{149} Use of the solid-phase binding to the specific antibodies avoids possible interferences within the bioluminescence detection system. Thus ATP or ATP-regenerating enzymes in plasma, such as adenylate kinase, cannot interfere as in the luminescence assay systems described for creatine kinase BB (11) . #{149} The coated tubes can be re-used. Acidifying the tubes after the assay by adding Tris-glycine buffer (pH 2.5) for 60 mm to liberate the bound enolase, then washing twice with assay buffer containing 10 g of bovine serum albumin per liter, produced no loss in antibody-binding capacity. This work was supported in part by the Stiftung Deutsche Krebshilfe.
